Biospring Partners

Power100 Presented By Blueprint Capital Advisors LLC is excited to announce the second cohort of the 2025 Power100 Asset Managers list.? This list recognizes distinguished individuals and firms in private markets strategies and a few standouts executing in the public markets.? It is a reflection of progress across the alternatives landscape as women and diverse professionals have established themselves and firms in niche strategies within the space.? They are represented within private equity, venture, private credit, structured equity, GP stakes where competition is always intense and the inputs are endless.? They are generating strong performance by driving portfolio company outcomes and navigating rapidly changing and more volatile markets.? These individuals and organizations are inspiring and impacting the industry and their beloved communities thereby helping to narrow societal gaps in areas such as gender, ethnicity, wealth, health, and education. The honorees are: 5th Century Partners Amateras AEA Ariel Alternatives Ascend Partners AUA Private Equity Partners Auldbrass Partners Awani Capital Management Avante Capital Partners BharCap Partners Biospring Partners Brightwood Capital CFI Partners Channing Capital Management Clearlake Capital Group Coalesce Capital Cross Rapids Capital Demopolis Equity Partners ? FVLCRUM Funds GenNx360 Capital Partners Grain Management, LLC GrowthCurve Capital HarbourView Equity Partners Heard Capital ICV Partners, LLC IMB Partners Invidia Capital Management Kah Capital Management, LLC Kingston Capital Management L2 Point Leap Global Partners Leeds Illuminate Metis Global Partners Nile Capital Group LLC New Catalyst Strategic Partners Ocean Park Investments Palladium Equity Partners, LLC Pharos Capital Group Reach Capital Red Arts Capital Siris Capital Group Stellex Capital Management Trident Turning Rock Partners Vista Equity Partners The Vistria Group Xponance, Inc. Other categories, including Endowments, Foundations and Advisors will be announced in the days to come. The Power100 will be honored at The 2nd Annual Honoree Dinner on May 4, 2025 at The Sofitel Los Angeles at Beverly Hills, California. For more information, visit www.power100family.com.

We are incredibly proud to announce that Abzena has received the Champion Award in the Biologics - Global category of the 2025 CDMO Leadership Awards. This recognition highlights our global team's unwavering commitment to providing exceptional service to our customers, enabling them to advance life-saving therapeutics for patients in need. As Kimberly Burrell, our Senior Vice President of Global Marketing, expresses, "We are a team based in the UK and the US, and we all come together to support our clients' needs with the highest standards of quality excellence." We extend our heartfelt gratitude to all our customers, collaborators, partners, and colleagues in the Abzena community. Together, we are shaping the future of biopharmaceutical development and manufacturing. Want to learn more about Abzena's end-to-end CDMO + CRO capabilities that support complex biologics & bioconjugates (ADCs/AOCs/RDCs), visit: https://lnkd.in/gJiywnC2 #DrugDevelopment #CDMO #CRO #Leadership

?? Today, we are thrilled to announce that ??????-???????? ???? ???????????? has been granted full qualification by the EMA CHMP, European Medicines Agency—making it the first and only AI-assisted pathology tool qualified for #histology enrollment and endpoint assessment in #MASH #clinicaltrials This qualification marks one of the most significant milestones in #AIPathology, bringing these tools closer than ever to making a direct impact on patients living with MASH. ??? Read the #PressRelease: https://lnkd.in/eGpP_NT5 AIM-MASH AI Assist provides a standardized, scalable, and AI-powered approach to evaluating liver biopsies, enabling #pathologists to enhance the analysis of complex tissue samples and aid in scoring patient samples for critical, life-saving clinical trials for MASH—a disease affecting over 52 million people in Europe. ?? Why this matters: - First AI-assisted #pathology tool qualified by EMA for MASH trials - Enables histology-based enrollment and primary/secondary endpoint assessment - Supports single-central pathologist workflows, reducing variability and increasing efficiency - Fully validated, ensuring accurate and reliable assessments "This achievement underscores our commitment to leveraging AI to transform pathology and improve patient outcomes. We believe that AIM-MASH AI Assist will play a crucial role in advancing MASH research and bringing much-needed therapies to patients," said Andrew Beck, CEO of PathAI. ??????-???????? ???? ???????????? ???? ?????? ???????????????? ?????? ????????. ?????? ?????? ?????? ???? ???????????????????? ????????????????????

It’s a bustling morning at DCAT Week in NYC. Abzena is sponsoring two talks today in the Grand Ballroom at the Intercontinental Barclay on Achieving Supply Chain Resilency at 11am and the keynote session at 1:30pm entitled “What’s on the Horizon: New Modalities & Promising Drug Classes.” Make sure to swing by our table top outside the ballroom to connect with our drug development experts -or- schedule some time to meet with our leadership in our meeting rooms at the Lotte Palace. We look forward to the conversation! To schedule a meeting visit: https://lnkd.in/e3eyX_DM #dcat #drugdevelopment #CDMO #CRO

Please join us next week for our March Bits in Bio Boston chapter event, co-sponsored by?Labviva?and?Biospring Partners! This event is a premier opportunity for those in the Boston area passionate about the intersection of software, AI/ML, and business applications, with a special focus on procurement. We’ll explore how AI is transforming procurement strategies and operations, from streamlining supplier management to automating purchasing processes and improving decision-making. A series of lightning talks will showcase how businesses are harnessing AI to drive efficiency, reduce costs, and foster innovation in procurement and beyond. The venue has limited capacity, so be sure to reserve your ticket while they’re still available. Light food and drinks will be provided. Logistics: - Date and time:?Thursday, March 6th from 5:30-7:30pm - Please register here:?https://lu.ma/wc9qjubf

ixlayer is excited to be named to the Digital Health New York 100, joining the ranks of past winners Capsule, Maven Clinic, Oscar Health, Ro, Sword Health, Talkiatry, Talkspace and Zocdoc. Read more in today's press release: https://lnkd.in/e_wtDkut

?? Big news from Ncardia! We're proud to introduce Ncyte? Microglia and Ncyte? Heart in a Box—two innovative hiPSC products designed to advance CNS and cardiac research. ?? Ncyte? Microglia: hiPSC-derived microglia advancing research into Alzheimer’s, Parkinson’s, ALS, and more. Read the full release here: https://lnkd.in/d85e4w9S ?? Ncyte? Heart in a Box: A 3D cardiac microtissue model replicating human heart complexity. Read the full release here: https://lnkd.in/dZh84YaV Learn how our innovations can empower your research: https://lnkd.in/d2h5nQ4t This project is made possible in part by a contribution from the National Growth Fund program NXTGEN Hightech. #hiPSC #LifeSciences #Innovation #SLAS

Labviva recently announced its $25M Series B round of funding led by 53 Stations with participation from Biospring Partners, Glasswing Ventures, & B Capital - I connected with Siamak Baharloo, Labviva's CEO & Co-Founder to get the latest at the company. In this video, we discuss: * Details about Labviva * Latest Round of Funding * Growth plans * The culture at Labviva * Why now is an ideal time to join Labviva #seriesb #funding #venturecapital

Biospring Partners is pleased to announce the promotion of Socrates Zacharias to Principal and welcomes two new Operating Partners: Chad Hooper and Jivan Achreja. More here: https://lnkd.in/dDdc7HnR Michelle Detwiler / Jennifer Lum / Jordan Feyko / Matt McBryan / Sid Nambiar

Labviva, the leading AI procurement platform for life sciences, has raised a $25M Series B. Congratulations Siamak Baharloo, Nicholas Rioux, and team!